Symbols / MRNA
MRNA Chart
About
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax , mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 19.95B |
| Enterprise Value | 15.37B | Income | -2.82B | Sales | 1.94B |
| Book/sh | 21.95 | Cash/sh | 14.68 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4700 | IPO | — |
| P/E | — | Forward P/E | -11.08 | PEG | — |
| P/S | 10.26 | P/B | 2.33 | P/C | — |
| EV/EBITDA | -5.38 | EV/Sales | 7.91 | Quick Ratio | 3.06 |
| Current Ratio | 3.29 | Debt/Eq | 15.09 | LT Debt/Eq | — |
| EPS (ttm) | -7.26 | EPS next Y | -4.61 | EPS Growth | — |
| Revenue Growth | -29.80% | Earnings | 2026-04-30 | ROA | -14.51% |
| ROE | -28.87% | ROIC | — | Gross Margin | -105.76% |
| Oper. Margin | -126.40% | Profit Margin | -145.16% | Shs Outstand | 390.73M |
| Shs Float | 368.36M | Short Float | 22.25% | Short Ratio | 5.08 |
| Short Interest | — | 52W High | 55.20 | 52W Low | 22.28 |
| Beta | 1.34 | Avg Volume | 11.69M | Volume | 4.59M |
| Target Price | $42.05 | Recom | Hold | Prev Close | $50.29 |
| Price | $51.06 | Change | 1.53% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$42.05
Mean price target
2. Current target
$50.52
Latest analyst target
3. DCF / Fair value
$-61.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$50.52
Low
$12.00
High
$135.00
Mean
$42.05
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | main | Piper Sandler | Overweight → Overweight | $69 |
| 2026-02-17 | main | Goldman Sachs | Neutral → Neutral | $41 |
| 2026-02-17 | main | RBC Capital | Sector Perform → Sector Perform | $30 |
| 2026-02-17 | main | Evercore ISI Group | In-Line → In-Line | $35 |
| 2025-12-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $28 |
| 2025-12-12 | init | Jefferies | — → Hold | $30 |
| 2025-11-21 | reit | Piper Sandler | Overweight → Overweight | $63 |
| 2025-11-21 | main | RBC Capital | Sector Perform → Sector Perform | $25 |
| 2025-11-21 | main | Leerink Partners | Underperform → Underperform | $18 |
| 2025-11-10 | main | B of A Securities | Underperform → Underperform | $21 |
| 2025-11-07 | main | Barclays | Equal-Weight → Equal-Weight | $25 |
| 2025-10-23 | main | UBS | Buy → Buy | $40 |
| 2025-10-23 | main | JP Morgan | Underweight → Underweight | $25 |
| 2025-10-23 | main | Citigroup | Neutral → Neutral | $28 |
| 2025-10-20 | reit | Needham | Hold → Hold | — |
| 2025-10-10 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $32 |
| 2025-08-22 | main | Leerink Partners | Underperform → Underperform | $15 |
| 2025-08-04 | main | Barclays | Equal-Weight → Equal-Weight | $31 |
| 2025-07-22 | main | B of A Securities | Underperform → Underperform | $25 |
| 2025-05-22 | main | JP Morgan | Underweight → Underweight | $26 |
- Moderna Stock: How Far Can The Flu Shot Fly? - Forbes ue, 24 Feb 2026 15
- Piper Sandler raises Moderna stock price target on vaccine pipeline - Investing.com Mon, 23 Feb 2026 14
- Why Moderna (MRNA) Stock Is Trading Up Today - Yahoo Finance Wed, 18 Feb 2026 20
- Moderna, Inc. (MRNA) Stock Analysis: Navigating a -15.68% Potential Downside Amid Revenue Challenges - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- Is Moderna (MRNA) Pricing Reflect Its mRNA Pipeline Potential After 62% Year To Date Rally - simplywall.st Mon, 23 Feb 2026 07
- Aberdeen Group plc Reduces Stock Holdings in Moderna, Inc. $MRNA - MarketBeat Mon, 23 Feb 2026 08
- What the Options Market Tells Us About Moderna - Benzinga ue, 24 Feb 2026 20
- Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda - Fox Business Wed, 04 Feb 2026 08
- Why Is Moderna (MRNA) Stock Rocketing Higher Today - Yahoo Finance Fri, 19 Dec 2025 08
- Vanguard Group Inc. Has $1.06 Billion Stock Position in Moderna, Inc. $MRNA - MarketBeat Sun, 22 Feb 2026 12
- Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here? - Yahoo Finance Wed, 18 Feb 2026 21
- 500,000 Shares in Moderna, Inc. $MRNA Bought by Telemark Asset Management LLC - MarketBeat Sun, 22 Feb 2026 13
- Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance Mon, 02 Feb 2026 08
- Why Moderna (MRNA) Stock Is Trading Lower Today - Yahoo Finance Fri, 31 Oct 2025 07
- Why Moderna (MRNA) Stock Is Up Today - Yahoo Finance hu, 18 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2630 | — | — | Stock Award(Grant) at price 0.00 per share. | KLINGER SHANNON THYME | Officer | — | 2026-02-11 00:00:00 | D |
| 1 | 4884 | — | — | Stock Award(Grant) at price 0.00 per share. | HOGE STEPHEN | President | — | 2026-02-11 00:00:00 | D |
| 2 | 11271 | — | — | Stock Award(Grant) at price 0.00 per share. | BANCEL STEPHANE J | Chief Executive Officer | — | 2026-02-11 00:00:00 | D |
| 3 | 2630 | — | — | Stock Award(Grant) at price 0.00 per share. | MOCK JAMES M | Chief Financial Officer | — | 2026-02-11 00:00:00 | D |
| 4 | 1452 | nan | — | — | MOCK JAMES M | Chief Financial Officer | — | 2026-01-05 00:00:00 | D |
| 5 | 23853 | 703306.0 | — | Sale at price 29.48 per share. | AFEYAN NOUBAR BOGHOS | Director | — | 2025-12-11 00:00:00 | I |
| 6 | 23853 | 259998.0 | — | Conversion of Exercise of derivative security at price 10.90 per share. | AFEYAN NOUBAR BOGHOS | Director | — | 2025-12-11 00:00:00 | I |
| 7 | 688073 | 7499996.0 | — | Conversion of Exercise of derivative security at price 10.90 per share. | BANCEL STEPHANE J | Chief Executive Officer | — | 2025-12-11 00:00:00 | D |
| 8 | 504 | 13910.0 | — | Sale at price 27.60 per share. | HUSSAIN SHAH ABBAS | Director | — | 2025-12-09 00:00:00 | D |
| 9 | 47190 | nan | — | — | KLINGER SHANNON THYME | Officer | — | 2025-12-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -728.00K | -15.12M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.01 | 0.21 | 0.13 | 0.08 |
| NormalizedEBITDA | -3.34B | -3.21B | 9.77B | 13.53B |
| TotalUnusualItems | -56.00M | -72.00M | -20.00M | 1.00M |
| TotalUnusualItemsExcludingGoodwill | -56.00M | -72.00M | -20.00M | 1.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.56B | -4.71B | 8.36B | 12.20B |
| ReconciledDepreciation | 189.00M | 621.00M | 348.00M | 232.00M |
| ReconciledCostOfRevenue | 1.46B | 4.69B | 5.42B | 2.62B |
| EBITDA | -3.39B | -3.28B | 9.77B | 13.53B |
| EBIT | -3.58B | -3.90B | 9.42B | 13.30B |
| NetInterestIncome | 401.00M | 383.00M | 200.00M | 18.00M |
| InterestExpense | 24.00M | 38.00M | 29.00M | 18.00M |
| InterestIncome | 425.00M | 421.00M | 200.00M | 18.00M |
| NormalizedIncome | -3.51B | -4.66B | 8.36B | 12.20B |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.56B | -4.71B | 8.36B | 12.20B |
| TotalExpenses | 7.14B | 10.99B | 9.46B | 4.44B |
| TotalOperatingIncomeAsReported | -3.94B | -4.24B | 9.42B | 13.30B |
| DilutedAverageShares | 384.00M | 382.00M | 416.00M | 431.00M |
| BasicAverageShares | 384.00M | 382.00M | 394.00M | 403.00M |
| DilutedEPS | -9.28 | -12.33 | 20.12 | 28.29 |
| BasicEPS | -9.28 | -12.33 | 21.26 | 30.31 |
| DilutedNIAvailtoComStockholders | -3.56B | -4.71B | 8.36B | 12.20B |
| NetIncomeCommonStockholders | -3.56B | -4.71B | 8.36B | 12.20B |
| NetIncome | -3.56B | -4.71B | 8.36B | 12.20B |
| NetIncomeIncludingNoncontrollingInterests | -3.56B | -4.71B | 8.36B | 12.20B |
| NetIncomeContinuousOperations | -3.56B | -4.71B | 8.36B | 12.20B |
| TaxProvision | -46.00M | 772.00M | 1.21B | 1.08B |
| PretaxIncome | -3.61B | -3.94B | 9.57B | 13.29B |
| OtherIncomeExpense | -63.00M | -86.00M | -45.00M | -29.00M |
| OtherNonOperatingIncomeExpenses | -7.00M | -14.00M | -45.00M | -29.00M |
| GainOnSaleOfSecurity | -56.00M | -72.00M | -20.00M | 1.00M |
| NetNonOperatingInterestIncomeExpense | 401.00M | 383.00M | 200.00M | 18.00M |
| InterestExpenseNonOperating | 24.00M | 38.00M | 29.00M | 18.00M |
| InterestIncomeNonOperating | 425.00M | 421.00M | 200.00M | 18.00M |
| OperatingIncome | -3.94B | -4.24B | 9.42B | 13.30B |
| OperatingExpense | 5.68B | 6.30B | 4.04B | 1.82B |
| OtherOperatingExpenses | -37.00M | -94.00M | -388.00M | -735.00M |
| ResearchAndDevelopment | 4.54B | 4.84B | 3.29B | 1.99B |
| SellingGeneralAndAdministration | 1.17B | 1.55B | 1.13B | 567.00M |
| GrossProfit | 1.74B | 2.06B | 13.46B | 15.12B |
| CostOfRevenue | 1.46B | 4.69B | 5.42B | 2.62B |
| TotalRevenue | 3.20B | 6.75B | 18.88B | 17.74B |
| OperatingRevenue | 4.52B | 8.20B | 18.43B | 17.68B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 386.00M | 382.00M | 385.00M | 403.00M |
| ShareIssued | 386.00M | 382.00M | 385.00M | 403.00M |
| TotalDebt | 747.00M | 1.24B | 1.20B | 916.00M |
| TangibleBookValue | 10.81B | 13.76B | 19.12B | 14.14B |
| InvestedCapital | 10.90B | 13.85B | 19.12B | 14.14B |
| WorkingCapital | 5.89B | 7.31B | 8.51B | 6.94B |
| NetTangibleAssets | 10.81B | 13.76B | 19.12B | 14.14B |
| CapitalLeaseObligations | 747.00M | 1.24B | 1.20B | 916.00M |
| CommonStockEquity | 10.90B | 13.85B | 19.12B | 14.14B |
| TotalCapitalization | 10.90B | 13.85B | 19.12B | 14.14B |
| TotalEquityGrossMinorityInterest | 10.90B | 13.85B | 19.12B | 14.14B |
| StockholdersEquity | 10.90B | 13.85B | 19.12B | 14.14B |
| GainsLossesNotAffectingRetainedEarnings | -10.00M | -123.00M | -370.00M | -24.00M |
| OtherEquityAdjustments | -10.00M | -123.00M | -370.00M | -24.00M |
| RetainedEarnings | 10.04B | 13.61B | 18.32B | 9.96B |
| AdditionalPaidInCapital | 866.00M | 371.00M | 1.17B | 4.21B |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.24B | 4.57B | 6.74B | 10.52B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.03B | 1.56B | 1.81B | 1.40B |
| OtherNonCurrentLiabilities | 36.00M | 21.00M | 135.00M | 76.00M |
| TradeandOtherPayablesNonCurrent | 231.00M | 235.00M | ||
| NonCurrentDeferredLiabilities | 58.00M | 83.00M | 673.00M | 615.00M |
| NonCurrentDeferredRevenue | 58.00M | 83.00M | 673.00M | 615.00M |
| LongTermDebtAndCapitalLeaseObligation | 710.00M | 1.22B | 1.00B | 705.00M |
| LongTermCapitalLeaseObligation | 710.00M | 1.22B | 1.00B | 705.00M |
| CurrentLiabilities | 2.21B | 3.02B | 4.92B | 9.13B |
| OtherCurrentLiabilities | 181.00M | 41.00M | 53.00M | 14.00M |
| CurrentDeferredLiabilities | 153.00M | 568.00M | 2.04B | 6.25B |
| CurrentDeferredRevenue | 153.00M | 568.00M | 2.04B | 6.25B |
| CurrentDebtAndCapitalLeaseObligation | 37.00M | 25.00M | 196.00M | 211.00M |
| CurrentCapitalLeaseObligation | 37.00M | 25.00M | 196.00M | 211.00M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 312.00M | 245.00M | 190.00M | 126.00M |
| CurrentProvisions | 370.00M | 556.00M | ||
| PayablesAndAccruedExpenses | 1.15B | 1.58B | 2.45B | 2.52B |
| CurrentAccruedExpenses | 745.00M | 997.00M | 1.91B | 1.35B |
| Payables | 408.00M | 583.00M | 535.00M | 1.18B |
| TotalTaxPayable | 3.00M | 63.00M | 48.00M | 876.00M |
| IncomeTaxPayable | 3.00M | 63.00M | 48.00M | 876.00M |
| AccountsPayable | 405.00M | 520.00M | 487.00M | 302.00M |
| TotalAssets | 14.14B | 18.43B | 25.86B | 24.67B |
| TotalNonCurrentAssets | 6.04B | 8.10B | 12.43B | 8.60B |
| OtherNonCurrentAssets | 171.00M | 181.00M | 946.00M | 46.00M |
| NonCurrentPrepaidAssets | 139.00M | 342.00M | 0.00 | |
| NonCurrentDeferredAssets | 81.00M | 81.00M | 982.00M | 326.00M |
| NonCurrentDeferredTaxesAssets | 81.00M | 81.00M | 982.00M | 326.00M |
| NonCurrentAccountsReceivable | 97.00M | |||
| InvestmentsAndAdvances | 2.51B | 4.74B | 8.36B | 6.84B |
| InvestmentinFinancialAssets | 2.49B | 4.68B | 8.32B | 6.84B |
| AvailableForSaleSecurities | 2.49B | 4.68B | 8.32B | 6.84B |
| LongTermEquityInvestment | 14.00M | 66.00M | 42.00M | |
| GoodwillAndOtherIntangibleAssets | 92.00M | 96.00M | 0.00 | |
| OtherIntangibleAssets | 40.00M | 44.00M | ||
| Goodwill | 52.00M | 52.00M | 0.00 | |
| NetPPE | 2.96B | 2.66B | 2.14B | 1.38B |
| AccumulatedDepreciation | -527.00M | -433.00M | -658.00M | -352.00M |
| GrossPPE | 3.48B | 3.09B | 2.80B | 1.74B |
| Leases | 207.00M | 522.00M | 460.00M | 313.00M |
| ConstructionInProgress | 1.06B | 860.00M | 281.00M | 212.00M |
| OtherProperties | 1.24B | 1.59B | 1.99B | 1.17B |
| MachineryFurnitureEquipment | 181.00M | 100.00M | 59.00M | 36.00M |
| BuildingsAndImprovements | 743.00M | 0.00 | ||
| LandAndImprovements | 59.00M | 22.00M | 11.00M | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.10B | 10.32B | 13.43B | 16.07B |
| OtherCurrentAssets | 58.00M | 88.00M | 44.00M | 26.00M |
| HedgingAssetsCurrent | 21.00M | |||
| PrepaidAssets | 307.00M | 350.00M | 851.00M | 554.00M |
| Inventory | 117.00M | 202.00M | 949.00M | 1.44B |
| FinishedGoods | 28.00M | 24.00M | 169.00M | 233.00M |
| WorkInProcess | 26.00M | 15.00M | 205.00M | 338.00M |
| RawMaterials | 63.00M | 163.00M | 575.00M | 870.00M |
| Receivables | 592.00M | 1.08B | 1.69B | 3.32B |
| OtherReceivables | 58.00M | 61.00M | 53.00M | 51.00M |
| TaxesReceivable | 117.00M | 69.00M | 150.00M | 70.00M |
| AccruedInterestReceivable | 59.00M | 59.00M | 61.00M | 27.00M |
| NotesReceivable | 0.00 | 36.00M | 0.00 | |
| AccountsReceivable | 358.00M | 892.00M | 1.39B | 3.17B |
| AllowanceForDoubtfulAccountsReceivable | -340.00M | -692.00M | 0.00 | 0.00 |
| GrossAccountsReceivable | 698.00M | 1.58B | 1.39B | 3.17B |
| CashCashEquivalentsAndShortTermInvestments | 7.03B | 8.60B | 9.90B | 10.73B |
| OtherShortTermInvestments | 5.10B | 5.70B | 6.70B | 3.88B |
| CashAndCashEquivalents | 1.93B | 2.91B | 3.21B | 6.85B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.05B | -3.83B | 4.58B | 13.34B |
| RepurchaseOfCapitalStock | 0.00 | -1.15B | -3.33B | -857.00M |
| RepaymentOfDebt | -140.00M | |||
| IssuanceOfCapitalStock | 66.00M | 46.00M | 65.00M | 124.00M |
| CapitalExpenditure | -1.05B | -707.00M | -400.00M | -284.00M |
| InterestPaidSupplementalData | 24.00M | 39.00M | 25.00M | 14.00M |
| IncomeTaxPaidSupplementalData | 197.00M | 2.73B | 480.00M | |
| EndCashPosition | 1.93B | 2.93B | 3.22B | 6.86B |
| BeginningCashPosition | 2.93B | 3.22B | 6.86B | 2.64B |
| ChangesInCash | -999.00M | -289.00M | -3.64B | 4.22B |
| FinancingCashFlow | 56.00M | -1.38B | -3.45B | -873.00M |
| CashFlowFromContinuingFinancingActivities | 56.00M | -1.38B | -3.45B | -873.00M |
| ProceedsFromStockOptionExercised | 46.00M | 65.00M | 124.00M | |
| NetCommonStockIssuance | 66.00M | -1.11B | -3.26B | -733.00M |
| CommonStockPayments | 0.00 | -1.15B | -3.33B | -857.00M |
| CommonStockIssuance | 66.00M | 46.00M | 65.00M | 124.00M |
| NetIssuancePaymentsOfDebt | -10.00M | -270.00M | -184.00M | -140.00M |
| NetLongTermDebtIssuance | -10.00M | -270.00M | -184.00M | -140.00M |
| LongTermDebtPayments | -140.00M | |||
| InvestingCashFlow | 1.95B | 4.21B | -5.18B | -8.52B |
| CashFlowFromContinuingInvestingActivities | 1.95B | 4.21B | -5.18B | -8.52B |
| NetOtherInvestingChanges | -23.00M | -40.00M | -30.00M | |
| NetInvestmentPurchaseAndSale | 3.00B | 5.02B | -4.74B | -8.21B |
| SaleOfInvestment | 9.53B | 8.78B | 6.70B | 4.44B |
| PurchaseOfInvestment | -6.53B | -3.76B | -11.44B | -12.65B |
| NetBusinessPurchaseAndSale | 0.00 | -85.00M | 0.00 | 0.00 |
| PurchaseOfBusiness | 0.00 | -85.00M | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -1.05B | -707.00M | -400.00M | -284.00M |
| PurchaseOfPPE | -1.05B | -707.00M | -400.00M | -284.00M |
| OperatingCashFlow | -3.00B | -3.12B | 4.98B | 13.62B |
| CashFlowFromContinuingOperatingActivities | -3.00B | -3.12B | 4.98B | 13.62B |
| ChangeInWorkingCapital | -78.00M | 689.00M | -4.01B | 1.31B |
| ChangeInOtherWorkingCapital | -439.00M | -2.06B | -4.16B | 2.82B |
| ChangeInOtherCurrentLiabilities | 106.00M | 639.00M | -754.00M | 140.00M |
| ChangeInOtherCurrentAssets | -53.00M | -605.00M | 21.00M | -58.00M |
| ChangeInPayablesAndAccruedExpense | -454.00M | -327.00M | 852.00M | 2.07B |
| ChangeInAccruedExpense | -385.00M | -340.00M | 612.00M | 989.00M |
| ChangeInPayable | -69.00M | 13.00M | 240.00M | 1.08B |
| ChangeInAccountPayable | -69.00M | 13.00M | 240.00M | 204.00M |
| ChangeInTaxPayable | 15.00M | -828.00M | 876.00M | |
| ChangeInIncomeTaxPayable | 15.00M | -828.00M | 876.00M | |
| ChangeInPrepaidAssets | 145.00M | 1.80B | -2.26B | -489.00M |
| ChangeInInventory | 83.00M | 747.00M | 492.00M | -1.39B |
| ChangeInReceivables | 534.00M | 493.00M | 1.79B | -1.78B |
| ChangesInAccountReceivables | 534.00M | 493.00M | 1.79B | -1.78B |
| OtherNonCashItems | 60.00M | 7.00M | 28.00M | |
| StockBasedCompensation | 429.00M | 305.00M | 226.00M | 142.00M |
| AmortizationOfSecurities | -95.00M | -61.00M | 31.00M | 54.00M |
| DeferredTax | 828.00M | -559.00M | -318.00M | |
| DeferredIncomeTax | 828.00M | -559.00M | -318.00M | |
| DepreciationAmortizationDepletion | 189.00M | 621.00M | 348.00M | 232.00M |
| DepreciationAndAmortization | 189.00M | 621.00M | 348.00M | 232.00M |
| OperatingGainsLosses | 52.00M | 35.00M | ||
| EarningsLossesFromEquityInvestments | 52.00M | 35.00M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -3.56B | -4.71B | 8.36B | 12.20B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MRNA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|